TITLE

Çocukluk Çağı Kronik Günlük Bafl Ağrılarında Topiramat Tedavisinin Etkinliği ve Güvenilirliği

AUTHOR(S)
Parlak, Adem; Dikililer, Aytuğ; Aydoğan, Ümit; Vurucu, Sebahattin; Ünay, Bülent; Akın, Rıdvan
PUB. DATE
April 2010
SOURCE
Journal of Current Pediatrics / Guncel Pediatri;2010, Vol. 8 Issue 1, p20
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Introduction: In this study, the effectiveness and safety of topiramate treatment in children with chronic daily headache were investigated. Materials and Method: This study was perfomed prospectively among 100 children who were diagnosed with chronic daily headache. Before the treatment, Pediatric Migraine Disability Assesment (PEDMİDAS) scores and grades of the patients were determined. Topiramate was given as 1 mg/kg/day then the dose was increased to 2 mg/kg/day at the tenth day of the treatment. At the third month, PEDMİDAS scores and grades were redetermined and compared with the first one. Results: The PEDMİDAS scores of the patients before and after the treatment were found as 34.60±22.28, 12.77±12.2, respectively. There was a statistical difference between these two values (p<0.001). When we group the patients according to the PEDMİDAS scores before the treatment 68% of the patients were grouped as grade 4, 23% as grade 3, 6% as grade 2 and 3% as grade 1; then after the treatment these percentages changed as 38.4% for grade 4, 29.4% for grade 3, 21.5% for grade 2 and 10.7% for grade1, respectively. Also forgetfulness in 8.8% (n=6) of patients, weight loss (average 250 grams) in 5.8% (n=4) and paresthesia in 4.4% (n=3) were determined. Conclusions: This study has shown that topiramate is safe, well tolerable and can be used with low doses in the treatment of chronic daily headache in childhood and is an alternative treatment choice that can be used in case no answers with other drugs.
ACCESSION #
51010618

 

Related Articles

  • Topiramate withdrawal.  // Reactions Weekly;6/2/2007, Issue 1154, p22 

    The article presents a case report of an obese man who experienced rebound weight gain following topiramate withdrawal. The man had a body mass index of 32 and a history of multiple dietary treatments followed by weight gain and an unsuccessful orlistat treatment. The man stopped further...

  • The skinny on errors with obesity drug names.  // Pharmacy Today;May2015, Vol. 21 Issue 5, p88 

    The article offers information on medications related to or used in the treatment of obesity. Topics discussed include potential confusion between the trade names Xeloda, an anticancer medication, and Xenical, an antiobesity drug, rules created by a hospital unto its computer system to alert...

  • Phentermine and Topiramate.  // AHFS Consumer Medication Information;Aug2019, p1 

    Phentermine and topiramate extended-release (long-acting) capsules are used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and to keep from gaining back that weight. Phentermine and topiramate extended-release capsules must be used...

  • Weight Regain after Discontinuation of Topiramate Treatment in Patients with Migraine: a Prospective Observational Study. Verrotti, Alberto; Parisi, Pasquale; Agostinelli, Sergio; Loiacono, Giulia; Marra, Francesca; Coppola, Giangennaro; Pisani, Laura; Gorgone, Gaetano; Striano, Pasquale; Pisani, Francesco; Belcastro, Vincenzo // CNS Drugs;Feb2015, Vol. 29 Issue 2, p163 

    Purpose: To monitor weight regain after therapy discontinuation in patients with migraine experiencing weight loss during topiramate (TPM) treatment. Methods: Patients with migraine without aura were enrolled in this observational prospective study. Weight, body mass index (BMI), waist...

  • Phentermine/Topiramate (Qsymia) for Chronic Weight Management. GAZEWOOD, JOHN D.; BARRY, KATHLEEN // American Family Physician;10/15/2014, Vol. 90 Issue 8, p576 

    The article presents a drug review on the mechanism of action and efficacy of phentermine/topiramate (Qsymia) for chronic weight management. Topics discussed include potential safety issues in using the drug such as nephrolithiasis, cardiac risk, and teratogenicity, common side effects of the...

  • Review of the pharmacologic arsenal for the war on obesity. Derbyshire, Mary Beth; Shek, Allen; Szkotak, Jonathan // Formulary;Apr2013, Vol. 48 Issue 4, p136 

    Obesity has become a highly prevalent chronic condition that is associated with significant morbidity and mortality. Studies have demonstrated that even as little as 5% to 10% of weight loss is associated with an improvement in cardiovascular risk factors and a reduction in the incidence of type...

  • Topiramate overdose.  // Reactions Weekly;10/9/2010, Issue 1322, p30 

    The article describes the case of a 37-year-old woman who went into a coma and acquired metabolic acidosis due to intentional overdose of topiramate to commit suicide.

  • Topiramate.  // Reactions Weekly;7/3/2010, Issue 1308, p32 

    The article describes the case of a mentally disabled woman who developed non-anion gap metabolic acidosis while receiving topiramate therapy,

  • Topiramate.  // Reactions Weekly;4/17/2010, Issue 1297, p48 

    The article describes the case of a 34-year-old woman who acquired acute transient myopia while undergoing treatment with topiramate.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics